These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 21638278)

  • 21. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.
    Aoki Y; Watanabe M; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
    Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration.
    Youssef RF; Shariat SF; Lotan Y; Wood CG; Sagalowsky AI; Zigeuner R; Kikuchi E; Weizer A; Raman JD; Remzi M; Kabbani W; Langner C; Guo CC; Roscigno M; Montorsi F; Bolenz C; Kassouf W; Margulis V
    BJU Int; 2011 Oct; 108(8):1286-91. PubMed ID: 21332905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?
    Brown GA; Busby JE; Wood CG; Pisters LL; Dinney CP; Swanson DA; Grossman HB; Pettaway CA; Munsell MF; Kamat AM; Matin SF
    BJU Int; 2006 Dec; 98(6):1176-80. PubMed ID: 17125474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
    Wei CH; Hsieh RK; Chiou TJ; Chen KK; Chang LS; Chen PM
    J Urol; 1996 Jan; 155(1):118-21. PubMed ID: 7490806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract.
    Cho KS; Joung JY; Seo HK; Cho IC; Chung HS; Chung J; Lee KH
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):769-74. PubMed ID: 20532510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers.
    Novara G; De Marco V; Gottardo F; Dalpiaz O; Bouygues V; Galfano A; Martignoni G; Patard JJ; Artibani W; Ficarra V
    Cancer; 2007 Oct; 110(8):1715-22. PubMed ID: 17724728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
    Tsai YS; Tzai TS; Chow NH
    Urol Int; 2007; 79(3):210-6. PubMed ID: 17940352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary urothelial carcinoma of the upper urinary tract in dialysis patients with 5-year follow-up.
    Kang CH; Chen CH; Chiang PH
    Jpn J Clin Oncol; 2010 Mar; 40(3):241-6. PubMed ID: 19933687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.
    Sonpavde G; Watson D; Tourtellott M; Cowey CL; Hellerstedt B; Hutson TE; Zhan F; Vogelzang NJ
    Clin Genitourin Cancer; 2012 Mar; 10(1):1-5. PubMed ID: 22340630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
    Nakagawa T; Komemushi Y; Kawai T; Otsuka M; Miyakawa J; Uemura Y; Kanatani A; Taguchi S; Naito A; Suzuki M; Nishimatsu H; Hirano Y; Tanaka Y; Matsumoto A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
    World J Urol; 2017 Oct; 35(10):1569-1575. PubMed ID: 28397000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract.
    Kwak C; Lee SE; Jeong IG; Ku JH
    Urology; 2006 Jul; 68(1):53-7. PubMed ID: 16806415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
    Hibi H; Okamura K; Takashi M; Shimoji T; Miyake K
    Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival.
    Ozyar E; Gurkaynak M; Yildiz F; Atahan IL
    Radiother Oncol; 2004 Jul; 72(1):71-7. PubMed ID: 15236877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration.
    Margulis V; Shariat SF; Matin SF; Kamat AM; Zigeuner R; Kikuchi E; Lotan Y; Weizer A; Raman JD; Wood CG;
    Cancer; 2009 Mar; 115(6):1224-33. PubMed ID: 19156917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG) study.
    Bamias A; Kyriakou F; Chorti M; Kavantzas N; Noni A; Kyroudi-Voulgari A; Rontoyianni D; Kastritis E; Xiros N; Patsouris ES; Murray S; Tamvakis N; Dimopoulos MA
    Anticancer Res; 2008; 28(4C):2479-86. PubMed ID: 18751438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive factors for bladder recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Cho DS; Kim SI; Ahn HS; Kim SJ
    Urol Int; 2013; 91(2):153-9. PubMed ID: 23391941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.